Investor Relations


Zogenix, Inc. (Nasdaq: ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
NASDAQ | ZGNX (Common Stock)
$39.65 + 0.65
Stock chart for: ZGNX.O.  Currently trading at $39.65 with a 52 week high of $41.80 and a 52 week low of $7.50.
Data as of 10/19/17 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.

Latest Presentations

Zogenix October 2017 Investor Presentation
Download Documentation

Recent News More

High Seizure Frequency in Children with Dravet Syndrome Negatively Impacts Quality of Life, New International Caregiver Survey Finds

Read More

Interim Survey Results Demonstrate Impact on Siblings of Children Suffering from Severe Epilepsy

Read More

Investor Events More

Tuesday, August 8, 2017 4:30 p.m. ET
Q2 2017 Zogenix, Inc. Earnings Conference Call